immunotoxin therapy

DRUG6 trials

Sponsors

National Cancer Institute (NCI), MedImmune LLC, Cambridge Antibody Technology

Conditions

HCLHairy Cell LeukemiaLeukemiaLymphomaNHLNon-Hodgkin's Lymphoma

Phase 1

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

WithdrawnNCT00024115

National Cancer Institute (NCI)Leukemia, Lymphoma

Updated: 2015-04-28

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

SuspendedNCT00077493

MedImmune LLCLeukemia, Lymphoma

Start: 2004-01-31End: 2008-10-31Target: 95Updated: 2007-12-28

BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

CompletedNCT00126646

MedImmune LLCLeukemia, Lymphoma

Start: 2005-06-30End: 2009-06-30Target: 24Updated: 2010-06-22

Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

Cambridge Antibody TechnologyLeukemia

Start: 2007-03-31Target: 50Updated: 2007-04-17

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Cambridge Antibody TechnologyHairy Cell Leukemia, HCL, Leukemia

Start: 2007-04-30Target: 40Updated: 2007-04-18

Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

Cambridge Antibody TechnologyLeukemia, NHL, Non-Hodgkin's Lymphoma

Start: 2007-08-31Target: 50Updated: 2007-08-14

Related Papers

Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia.

Journal of Clinical Oncology2015-05-201 citations

Soluble CD22 as a tumor marker for hairy cell leukemia.

2008-07-0224 citations